SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Life Scienc - Quaterly Results

27 Apr 2023 Evaluate
The Revenue for the quarter ended  March 2023 of Rs. 6213.20 millions grew by 20.87 % from Rs. 5140.57 millions.Net Profit recorded in the quarter ended March 2023 rise to 47.99% to Rs. 1463.57  millions  compared to R. 988.97 millions in corresponding previous quarter.OP of the company witnessed a marginal growth to 2092.66 millions from 1473.06 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 6213.20 5140.57 20.87 21612.20 21232.14 1.79 21612.20 21232.14 1.79
Other Income 28.36 50.95 -44.34 289.57 147.04 96.93 289.57 147.04 96.93
PBIDT 2092.66 1473.06 42.06 6712.50 6307.64 6.42 6712.50 6307.64 6.42
Interest 1.19 1.25 -4.80 5.47 279.62 -98.04 5.47 279.62 -98.04
PBDT 2091.47 1471.81 42.10 6707.03 6028.02 11.26 6707.03 6028.02 11.26
Depreciation 115.17 95.54 20.55 420.94 378.77 11.13 420.94 378.77 11.13
PBT 1976.30 1376.27 43.60 6286.09 5649.25 11.27 6286.09 5649.25 11.27
TAX 512.73 387.30 32.39 1616.48 1462.01 10.57 1616.48 1462.01 10.57
Deferred Tax 39.62 18.25 117.10 110.37 85.74 28.73 110.37 85.74 28.73
PAT 1463.57 988.97 47.99 4669.61 4187.24 11.52 4669.61 4187.24 11.52
Equity 245.05 245.05 0.00 245.05 245.05 0.00 245.05 245.05 0.00
PBIDTM(%) 33.68 28.66 17.54 31.06 29.71 4.55 31.06 29.71 4.55

Alivus Life Sciences Share Price

1066.65 -6.50 (-0.61%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×